UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the ...

Financial Data and Key Metrics Changes - Total sales for Q3 2024 were $316.7 million, a year-over-year increase of 4% as reported and 4.3% in constant currency [7] - GAAP net income for Q3 2024 was $49 million, compared to $15.8 million in Q3 2023, while adjusted net income increased 15% year-over-year to $32.7 million [8][32] - Adjusted diluted net earnings per share were $1.05, reflecting a 16.7% increase year-over-year [8][32] - Adjusted gross margin for Q3 was 56.5%, an increase of 60 basis points compared to the prior year [31] Business Line Data and Key Metrics Changes - U.S. orthopedic sales increased by 7.4%, while international orthopedic sales grew by 3.9% [26] - General Surgery revenue increased by 3.6% globally, with U.S. revenue growing by 7.4% but international revenue declining by 5% [28] - AirSeal capital sales in the U.S. continued strong growth, with no slowdown in demand for disposables [21][29] Market Data and Key Metrics Changes - U.S. sales increased by 7.4% compared to the prior year, while international sales grew by only 0.2% [26] - The orthopedic business showed resilience with a 5.2% growth worldwide, despite challenges in the supply chain [26] Company Strategy and Development Direction - The company is focused on improving service levels in the sports medicine space and addressing supply chain issues in orthopedics [27][23] - A succession plan was announced, with Pat Beyer set to take over as CEO, emphasizing a commitment to innovation and customer engagement [14][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of Hurricanes Helene and Milton on operations and production, which may affect Q4 results [24][35] - The company expects Q4 revenue to be between $339 million and $344 million, with full-year guidance adjusted to between $1.300 billion and $1.305 billion [37] Other Important Information - The company reported a cash balance of $38.5 million at the end of the quarter, an increase from $28.9 million [33] - Long-term debt decreased to $940 million, with a leverage ratio of 3.6 times [34] Q&A Session Summary Question: General Surgery performance and capital equipment revenues - Management explained that the decline in capital equipment revenues was due to last year's strong performance and backorders being resolved [40][41] Question: Orthopedic supply situation and future impact - Management confirmed progress in supply chain improvements but acknowledged that challenges may extend into 2025 [43][46] Question: Top priorities for 2025 - The new CEO emphasized focusing on customer engagement, employee connection, and advancing the company's growth [56] Question: Impact of IV fluid shortages on procedures - Management confirmed that hospitals have started reallocating and deferring procedures due to shortages, which has been factored into guidance [57] Question: Outlook for gross margins - Management expressed confidence in maintaining gross margin improvements, with expectations for Q4 around 57% [59] Question: Contingent consideration adjustments - Management clarified that adjustments were related to slower-than-expected performance in the foot and ankle business, but overall confidence in acquisitions remains strong [60][61]

For the quarter ended September 2024, Conmed (CNMD) reported revenue of $316.7 million, up 4% over the same period last year. EPS came in at $1.05, compared to $0.90 in the year-ago quarter. The reported revenue represents a surprise of -0.55% over the Zacks Consensus Estimate of $318.46 million. With the consensus EPS estimate being $0.99, the EPS surprise was +6.06%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 6.06%. A quarter ago, it was expected that this medical technology company would post earnings of $0.92 per share when it actually produced earnings of $0.98, delivering a surprise of 6.52%. Over the last four quarters, the ...

CONMED Investor Presentation Q3 2024 Earnings Call Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer Patrick Beyer Chief Operating Officer October 30, 2024 Forward-Looking Information 2 This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each classTrading SymbolName of each exchange on which registered Common Stock, $0.01 par value CNMD NYSE FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati ...

Conmed (CNMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 30. ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Conmed (CNMD) , which belongs to the Zacks Medical - Dental Supplies industry, could be a great candidate to consider. This medical technology company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.64%. For the last reported quarter, Conmed ...

CONMED Corporation (CNMD) is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid recurring revenue base and potential in General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist. Shares of this Zacks Rank #3 (Hold) company have lost 39.2% year to date compared with the industry's 1.7% fall. The S&P 500 Index has increased 20.6% in the same time frame. CONMED, a reno ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are ...